More than three decades ago, Congress created the 340B program to help safety-net hospitals and clinics​​ expand resources and care for underserved communities. By requiring pharmaceutical companies ...

Drugmakers’ 340B rebate fight, explained Johnson & Johnson, Eli Lilly, Sanofi and Bristol Myers Squibb are suing the federal government over the future of their 340B drug rebate plans.

A bipartisan Senate coalition missed its deadline to offer a 340B drug discount program overhaul. Its fate is murkier than ever as lawsuits abound.

New York hospitals that participate in 340B should be required to publicly report how much revenue they generate from the program.

Simple reforms can improve equity and maintain the intent of the 340B program. As taxpayers are both directly and indirectly funding the program, transparency is needed.

The past year has seen a great deal of controversy surrounding the 340B Drug Pricing Pr | The 340B drug pricing program has ballooned over the past decade, but the infrastructure to support it has ...

The pharmaceutical industry’s relentless, astronomically expensive campaign to smear the 340B Drug Pricing Program — one of the world’s most important humanitarian programs — knows no ...

Fortunately, the argument for SB14 is actually quite simple. Despite the ambiguity in the academic literature, the most obvious and direct effect of the program is indisputable: 340B drug ...

Despite rebukes by two federal circuit courts, an HHS sub-agency continues to overstep its authority when administering a drug-discount program.

Concerns regarding 340B drug discount program functioning have largely centered on whether these new participants are using 340B program benefits to improve access to care to low income patients ...